Skip to main content
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRDA ISIN · US29384C1080 US Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2025-02-14 Major Shareholding Noti…
Country US United States of America
Listing US TRDA

About Entrada Therapeutics, Inc.

https://www.entradatx.com/

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of medicines to treat devastating diseases. The company's proprietary Endosomal Escape Vehicle (EEV) platform is designed to enable the intracellular delivery of a wide range of therapeutics, allowing access to targets that have historically been considered undruggable. Entrada's development pipeline is concentrated on rare conditions, with programs targeting neuromuscular diseases, including Duchenne muscular dystrophy, as well as ocular diseases. The company's mission is to transform the lives of patients by establishing EEV-based therapeutics as a new treatment modality.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 3, 2025, by Entrada Therapeutics, Inc. It announces the receipt of authorization from UK regulatory bodies to initiate a Phase 1/2 clinical trial. The document includes a press release as an exhibit and forward-looking statements. There are no financial statements or detailed financial data included. The content is primarily an announcement of a regulatory event and clinical trial initiation, typical of a Regulatory Filing (RNS). The document length is 8241 characters, which is sufficient to contain substantive information but it is not a financial report or earnings release. It is not an Annual Report, Interim Report, Earnings Release, or any other specific report type. It is also not a report publication announcement since it contains the full text of the announcement. Therefore, the best classification is Regulatory Filings (RNS).
2025-02-03 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC by Entrada Therapeutics, Inc. dated January 15, 2025. It reports preliminary financial results for the fiscal year ended December 31, 2024, and includes a corporate presentation attached as an exhibit. The document explicitly states it is a "Current Report" and not a full annual or quarterly report. The content includes unaudited preliminary financial information and a presentation used at a healthcare conference, which aligns with a current report updating investors on recent events or financial condition. There is no full set of financial statements or comprehensive analysis typical of an Annual Report (10-K) or Interim Report (IR). The presence of a presentation and preliminary results in a Form 8-K is characteristic of a Capital/Financing Update or similar event-driven disclosure. However, since the document primarily provides preliminary financial results and a presentation at a conference, it fits best under the Capital/Financing Update (CAP) category, which covers updates on company financial conditions and capital resources. The document is not a full earnings release (ER) as it lacks key highlights and formal earnings announcement language, nor is it a Management Discussion and Analysis (MDA) as it lacks detailed management commentary. Therefore, the most appropriate classification is CAP with high confidence.
2025-01-15 English
Director's Dealing 2024
Director's Dealing
2024-12-12 English
Director's Dealing 2024
Director's Dealing
2024-12-12 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.